Opinion

Video

Adverse Effect Management and the Role of Immunotherapy in NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

Related Videos
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
Related Content
QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC
November 19th 2024

QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC

Hannah Clarke
At the time of data cutoff, 71% of patients achieved a complete response following treatment.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC
November 7th 2024

Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC

Hannah Clarke
At the end of the induction phase, 86% of patients had achieved a complete response.
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff
“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
Study to assess performance of CxBladder test in urothelial carcinoma surveillance
November 6th 2024

Study to assess performance of CxBladder test in urothelial carcinoma surveillance

Hannah Clarke
The observational LOBSTER study has already enrolled 303 patients and collected 479 samples.
TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma
October 31st 2024

TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma

Hannah Clarke
Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.
© 2024 MJH Life Sciences

All rights reserved.